UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241276812

Lazzaro, Carlo

2024

Volltextzugriff (PDF)

When cost-effectiveness analysis bites: Avoiding the pitfalls of extended dominance

Oral oncology, 2024-03, Vol.150, p.106724-106724, Article 106724

Lazzaro, Carlo

2024

Volltextzugriff (PDF)

Checking it (at least) twice may not be alright

The Journal of asthma, 2024-05, p.1-2

Lazzaro, Carlo

2024

Volltextzugriff (PDF)

Lazzaro responds to Pouwels et al

Breast cancer research and treatment, 2021-11, Vol.190 (1), p.1-1

Lazzaro, Carlo

2021

Volltextzugriff (PDF)

Letter to the Editor: Lazzaro responds to Kennedy et al

The European journal of health economics, 2024-06

Lazzaro, Carlo

2024

Volltextzugriff (PDF)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Journal of ophthalmology, 2022-04, Vol.2022, p.3837471-13

2022

Volltextzugriff (PDF)

Pharmacoeconomic issues in stem cell mobilization

Transfusion and apheresis science, 2023-12, Vol.62 (6), p.103829-103829, Article 103829

Lazzaro, Carlo

2023

Volltextzugriff (PDF)

AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis

Journal of rehabilitation medicine, 2020-02, Vol.52 (2), p.1

2020

Volltextzugriff (PDF)

Stata tip 150: When is it appropriate to xtset a panel dataset with panelvar only?

The Stata journal, 2023-03, Vol.23 (1), p.281-292

Lazzaro, Carlo

2023

Volltextzugriff (PDF)

Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al

The European journal of health economics, 2023-06, Vol.24 (4), p.661-662

Lazzaro, Carlo

2023

Volltextzugriff (PDF)

Consensus conference on the management of tumor lysis syndrome

Haematologica, 2008-12, Vol.93 (12), p.1877-1885

2008

Volltextzugriff (PDF)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study

Expert review of pharmacoeconomics & outcomes research, 2018-07, Vol.18 (4), p.435-446

2018

Volltextzugriff (PDF)

Brainstem cavernomas: long-term results of microsurgical resection in 52 patients

Neurosurgery, 2005-06, Vol.56 (6), p.1203-1214

2005

Volltextzugriff (PDF)

Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

Global & regional health technology assessment (Online), 2019-05, Vol.2019, p.228424031984394

2019

Volltextzugriff (PDF)

Angiographically proven cervical venous engorgement: a possible concurrent cause in the pathophysiology of Hirayama’s myelopathy

Neurological sciences, 2010-12, Vol.31 (6), p.845-848

2010

Volltextzugriff (PDF)

Cost of illness of advanced ovarian carcinoma in Italy: results of an empirical, single-centre study

Farmeconomia. Health economics and therapeutic pathways, 2015-09, Vol.16 (3), p.61-76

2015

Volltextzugriff (PDF)

Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis

Neurological sciences, 2014-07, Vol.35 (7), p.1023-1034

2014

Volltextzugriff (PDF)

Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model

Expert review of pharmacoeconomics & outcomes research, 2023-11, Vol.23 (10), p.1185-1200

2023

Volltextzugriff (PDF)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy

Neurological sciences, 2022-08, Vol.43 (8), p.4933-4944

2022

Volltextzugriff (PDF)

Second-look surgery for ependymoma: the Italian experience: Clinical article

Journal of neurosurgery. Pediatrics, 2011-09, Vol.8 (3), p.246-250

2011

Volltextzugriff (PDF)

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects

Farmeconomia. Health economics and therapeutic pathways, 2006-09, Vol.7 (2), p.89-96

Lazzaro, Carlo

2006

Volltextzugriff (PDF)

Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023

Expert review of pharmacoeconomics & outcomes research, 2024-06, Vol.24 (5), p.577-579

2024

Volltextzugriff (PDF)

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis

Bone marrow transplantation (Basingstoke), 2021-08, Vol.56 (8), p.1876-1887

2021

Volltextzugriff (PDF)

A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

Expert review of pharmacoeconomics & outcomes research, 2023-02, Vol.23 (2), p.251-265

2023

Volltextzugriff (PDF)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Journal of ophthalmology, 2022-04, Vol.2022

2022

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(198)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting

When cost-effectiveness analysis bites: Avoiding the pitfalls of extended dominance

Checking it (at least) twice may not be alright

Lazzaro responds to Pouwels et al

Letter to the Editor: Lazzaro responds to Kennedy et al

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Pharmacoeconomic issues in stem cell mobilization

AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis

Stata tip 150: When is it appropriate to xtset a panel dataset with panelvar only?

Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al

Consensus conference on the management of tumor lysis syndrome

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study

Brainstem cavernomas: long-term results of microsurgical resection in 52 patients

Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

Angiographically proven cervical venous engorgement: a possible concurrent cause in the pathophysiology of Hirayama’s myelopathy

Cost of illness of advanced ovarian carcinoma in Italy: results of an empirical, single-centre study

Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis

Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy

Second-look surgery for ependymoma: the Italian experience: Clinical article

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects

Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis

A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Suchergebnisse filtern